These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 23351788)

  • 1. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development.
    Ewing MM; Karper JC; Abdul S; de Jong RC; Peters HA; de Vries MR; Redeker A; Kuiper J; Toes RE; Arens R; Jukema JW; Quax PH
    Int J Cardiol; 2013 Oct; 168(3):1965-74. PubMed ID: 23351788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE(-/-) mice.
    Ma K; Lv S; Liu B; Liu Z; Luo Y; Kong W; Xu Q; Feng J; Wang X
    Cardiovasc Res; 2013 Feb; 97(2):349-59. PubMed ID: 23118130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
    Zhou T; Weaver C; Linsley PS; Mountz JD
    Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
    McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
    Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease.
    Tellander AC; Pettersson U; Runström A; Andersson M; Michaëlsson E
    J Autoimmun; 2001 Aug; 17(1):39-50. PubMed ID: 11488636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin.
    Mukherjee S; Maiti PK; Nandi D
    J Leukoc Biol; 2002 Nov; 72(5):921-31. PubMed ID: 12429713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells.
    Manzotti CN; Tipping H; Perry LC; Mead KI; Blair PJ; Zheng Y; Sansom DM
    Eur J Immunol; 2002 Oct; 32(10):2888-96. PubMed ID: 12355442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
    Mauri D; Wyss-Coray T; Gallati H; Pichler WJ
    J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86.
    Manzotti CN; Liu MK; Burke F; Dussably L; Zheng Y; Sansom DM
    Eur J Immunol; 2006 Jun; 36(6):1413-22. PubMed ID: 16708397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Cytotoxic T-Lymphocyte-Associated Antigen-4 Prevents Atherosclerosis in Mice.
    Matsumoto T; Sasaki N; Yamashita T; Emoto T; Kasahara K; Mizoguchi T; Hayashi T; Yodoi K; Kitano N; Saito T; Yamaguchi T; Hirata K
    Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1141-51. PubMed ID: 27055906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
    Habib-Agahi M; Phan TT; Searle PF
    Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive and negative regulation of human T cell activation mediated by the CTLA-4/CD28 ligand CD80.
    Boulougouris G; McLeod JD; Patel YI; Ellwood CN; Walker LS; Sansom DM
    J Immunol; 1998 Oct; 161(8):3919-24. PubMed ID: 9780158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.
    Freeman GJ; Lombard DB; Gimmi CD; Brod SA; Lee K; Laning JC; Hafler DA; Dorf ME; Gray GS; Reiser H
    J Immunol; 1992 Dec; 149(12):3795-801. PubMed ID: 1281186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses.
    Roy M; Aruffo A; Ledbetter J; Linsley P; Kehry M; Noelle R
    Eur J Immunol; 1995 Feb; 25(2):596-603. PubMed ID: 7533092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell regulation by CD28 and CTLA-4.
    Alegre ML; Frauwirth KA; Thompson CB
    Nat Rev Immunol; 2001 Dec; 1(3):220-8. PubMed ID: 11905831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.
    Salomon B; Bluestone JA
    Annu Rev Immunol; 2001; 19():225-52. PubMed ID: 11244036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
    J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo.
    Metzler B; Burkhart C; Wraith DC
    Int Immunol; 1999 May; 11(5):667-75. PubMed ID: 10330272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abatacept mechanism of action: concordance with its clinical profile.
    Herrero-Beaumont G; Martínez Calatrava MJ; Castañeda S
    Reumatol Clin; 2012; 8(2):78-83. PubMed ID: 22104048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2.
    Webb LM; Walmsley MJ; Feldmann M
    Eur J Immunol; 1996 Oct; 26(10):2320-8. PubMed ID: 8898940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.